Matinas BioPharma Holdings Management

Management criteria checks 3/4

Matinas BioPharma Holdings' CEO is Jerry Jabbour, appointed in Mar 2016, has a tenure of 8.08 years. total yearly compensation is $1.60M, comprised of 37.4% salary and 62.6% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth €76.81K. The average tenure of the management team and the board of directors is 5.3 years and 6.3 years respectively.

Key information

Jerry Jabbour

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage	37.4%
CEO tenure	8.1yrs
CEO ownership	0.2%
Management average tenure	5.3yrs
Board average tenure	6.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jerry Jabbour's remuneration changed compared to Matinas BioPharma Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$2m	US$598k	-US$23m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$21m
Dec 31 2022	US$2m	US$575k	-US$21m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$4m	US$545k	-US$24m
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$3m	US$500k	-US$23m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$1m	US$445k	-US$18m
Sep 30 2019	n/a	n/a	-US$16m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$15m
Dec 31 2018	US$1m	US$366k	-US$15m
Sep 30 2018	n/a	n/a	-US$15m
Jun 30 2018	n/a	n/a	-US$15m
Mar 31 2018	n/a	n/a	-US$16m
Dec 31 2017	US$1m	US$299k	-US$33m

Compensation vs Market: Jerry's total compensation ($USD1.60M) is above average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Jerry's compensation has been consistent with company performance over the past year.

CEO

Jerry Jabbour (49 yo)

8.1yrs

Tenure

US$1,599,551

Compensation

Mr. Jerome D. Jabbour, also known as Jerry, J. D., Co-founded Matinas BioPharma Holdings, Inc. and has been its Chief Executive Officer since March 16, 2018 and has been its President since March 7, 2016....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jerome Jabbour	Co-Founder	8.1yrs	US$1.60m	0.18% $ 76.8k
Theresa Matkovits	Chief Development Officer	5.5yrs	US$851.32k	no data
James Ferguson	Chief Medical Officer	5.2yrs	US$880.60k	no data
Keith Kucinski	Chief Financial Officer	5.3yrs	US$626.60k	0.038% $ 15.8k
Hui Liu	Chief Technology Officer	3.3yrs	no data	no data
Frank Calamusa	Executive Director and Head of Manufacturing & Supply Chain	5.5yrs	no data	no data
Thomas Hoover	Chief Business Officer	2.3yrs	no data	0% $ 0

5.3yrs

Average Tenure

54yo

Average Age

Experienced Management: 6LJ's management team is seasoned and experienced (5.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jerome Jabbour	Co-Founder	6.1yrs	US$1.60m	0.18% $ 76.8k
Herbert Conrad	Independent Director	10.8yrs	US$141.50k	1.87% $ 783.3k
James Scibetta	Independent Director	10.4yrs	US$155.00k	0.26% $ 108.5k
David Perlin	Member of Scientific Advisory Board	8.8yrs	no data	no data
Natasha Giordano	Independent Director	3.6yrs	US$145.50k	no data
Matthew Wikler	Independent Director	6.3yrs	US$136.00k	0.12% $ 48.5k
Eric Ende	Independent Chairman of the Board	7yrs	US$159.00k	0.057% $ 24.0k
J. Craft	Member of Scientific Advisory Board	no data	no data	no data
Patrick Flume	Member of Scientific Advisory Board	no data	no data	no data
Peter Pappas	Member of Scientific Advisory Board	no data	no data	no data
Oliver Cornely	Member of Scientific Advisory Board	6.3yrs	no data	no data
Dimitrios Kontoyiannis	Member of Scientific Advisory Board	6.3yrs	no data	no data

6.3yrs

Average Tenure

60yo

Average Age

Experienced Board: 6LJ's board of directors are considered experienced (6.3 years average tenure).

Matinas BioPharma Holdings Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022

Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022

Insufficient new directors

Insufficient new directors

Recent updates

New minor risk - Shareholder dilution

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Full year 2023 earnings released: US$0.11 loss per share (vs US$0.097 loss in FY 2022)

Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation

Matinas BioPharma Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA

Third quarter 2023 earnings released: US$0.028 loss per share (vs US$0.025 loss in 3Q 2022)

Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Matinas BioPharma Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient’s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203

No longer forecast to breakeven

Insufficient new directors

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases

Matinas BioPharma Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Matinas BioPharma Holdings, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.097 loss per share (vs US$0.11 loss in FY 2021)

Forecast to breakeven in 2025

Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.032 loss in 3Q 2021)

Matinas BioPharma Holdings, Inc. Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold, Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022

Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022

Second quarter 2022 earnings released: US$0.027 loss per share (vs US$0.024 loss in 2Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Insufficient new directors

Forecast to breakeven in 2024

Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final Cohort of Patients in the Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis

Matinas Biopharma Announces Positive Data in the Ongoing Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold

Forecast to breakeven in 2025

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®

Matinas BioPharma Holdings, Inc. Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001

New 90-day high: €1.37

Matinas Biopharma Holdings, Inc. Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas LNC Platform Delivery Technology

Matinas BioPharma Holdings, Inc. Appoints Hui Liu as Chief Technology Officer

New 90-day high: €0.84

Matinas BioPharma Holdings, Inc. Awards Up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients

Revenue beats expectations

Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

New 90-day low - €0.61

Earnings released

New 90-day high - €0.85

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age